GlassScriptPhysician profile
Hena Lonappan
NPI 1689432320
$3,138.03
in general payments reported to CMS, 2019-2025
18 companies · $39.37 in 2025
The $39.37 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,099 · 2025: $39.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $528.36 | 2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $507.23 | 2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $330.31 | 2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $309.78 | 2024 | Caplyta |
| Lundbeck LLC | $255.70 | 2024 | Rexulti |
| Alkermes, INC. | $253.73 | 2024 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $239.28 | 2024-2025 | |
| Axsome Therapeutics, INC. | $193.54 | 2024 | Auvelity |
| Corium, LLC | $99.60 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $92.03 | 2024 | |
| Ironshore Pharmaceuticals INC. | $91.26 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $57.84 | 2024 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $54.13 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $44.59 | 2024 | Trintellix |
| Biogen, INC. | $29.11 | 2024 | Zurzuvae |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.53 | 2024 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $17.45 | 2024 | Subvenite |
| Noven Therapeutics, LLC | $16.56 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hena Lonappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.